臨床検査54巻6号

2010年06月発行

今月の主題 注目されるサイトカイン 話題

サイトカインと癌治療

著者： 井上博之¹ 谷憲三朗¹

所属機関： ¹九州大学生体防御医学研究所・ゲノム機能制御学部門

ページ範囲：P.670 - P.676

1．はじめに

　悪性腫瘍は，世界的に罹患率および死亡率において最も重要な疾患であり，難治性疾患として今後も診断，治療など様々な面から新たな研究アプローチが必要とされている．近年，手術療法，抗癌剤治療，放射線治療，分子標的薬治療に加え，様々な腫瘍免疫療法の基礎研究，臨床研究が行われるようになった．腫瘍免疫療法は，樹状細胞やTリンパ球などの免疫細胞を用いた細胞療法，補体系やADCC(antibody dependent cell cytotoxicity)活性を利用したモノクローナル抗体療法などの多岐にわたるが，免疫応答(炎症)の主役を担うサイトカインおよびケモカインをアジュバント(免疫賦活剤)あるいは免疫担当細胞や腫瘍細胞に遺伝子導入して用いられるワクチン細胞療法(免疫遺伝子治療)が，有害事象の少ない新規治療法として注目を集めている¹⁾．

　本稿では，後者の免疫遺伝子治療にかかわる近年の報告を中心に展望を述べる．

参考文献

1) Dougan M, Dranoff G：Immune therapy for cancer. Annu Rev Immunol　27：83-117, 2009

2) Atkins MB, Lotze MT, Dutcher JP, et al：High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma：analysis of 270 patients treated between 1985 and 1993. J Clin Oncol　17：2105-2116, 1999

3) Kirkwood JM, Strawderman MH, Ernstoff MS, et al：Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma：the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol　14：7-17, 1996

4) Motzer RJ, Hutson TE, Tomczak P, et al：Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med　356：115-124, 2007

5) Grunhagen DJ, de Wilt JH, Graveland WJ, et al：Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer　106：1776-1784, 2006

6) Berinstein NL：Enhancing cancer vaccines with immunomodulators. Vaccine 25 (Suppl 2)：B72-B88, 2007

7) Fong L, Kwek SS, O'Brien S, et al：Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res　69：609-615, 2009

8) Amato RJ, Hernandez-McClain J, Henary H：Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate. Urol Oncol　27：8-13, 2009

9) Dranoff G, Jaffee E, Lazenby A, et al：Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA　90：3539-3543, 1993

results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. J Immunol　169：2875-2885, 2002

11) Tani K, Azuma M, Nakazaki Y, et al：Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan：clinical and immunological findings. Mol Ther　10：799-816, 2004

12) Eager R, Nemunaitis J：GM-CSF gene-transduced tumor vaccines. Mol Ther　12：18-27, 2005

13) Antonarakis ES, Drake CG：Current status of immunological therapies for prostate cancer. Curr Opin Urol［Epub ahead of print］

14) Jinushi M, Tahara H：Cytokine gene-mediated immunotherapy：current status and future perspectives. Cancer Sci　100：1389-1396, 2009

15) Lei N, Shen FB, Chang JH, et al：An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther　16：33-43, 2009

16) Lee JH, Roh MS, Lee YK, et al：Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther　17：73-79, 2010

17) Grote D, Cattaneo R, Fielding AK：Neutrophils contribute to the measles virus-induced antitumor effect：enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res　63：6463-6468, 2003

18) Stagg J, Wu JH, Bouganim N, et al：Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res　64：8795-8799, 2004

19) Wakimoto H, Abe J, Tsunoda R, et al：Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res　56：1828-1833, 1996

20) Kinoshita Y, Kono T, Yasumoto R, et al：Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells. J Immunother　24：205-211, 2001

21) Li B, VanRoey MJ, Jooss K：Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol　123：155-165, 2007

22) Chang CJ, Chen YH, Huang KW, et al：Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology　45：746-754, 2007

23) Prell RA, Li B, Lin JM, et al：Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine. Cancer Res　65：2449-2456, 2005

24) Smith KE, Janelidze S, Visse E, et al：Synergism between GM-CSF and IFNgamma：enhanced immunotherapy in mice with glioma. Int J Cancer　120：75-80, 2007

25) Inoue H, Iga M, Xin M, et al：TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol Immunother　57：1399-1411, 2008

immune gene therapy of cancer：combined strategies for treatment of systemic disease. Cancer Immunol Immunother　55：1443-1450, 2006

27) Sandler AD, Chihara H, Kobayashi G, et al：CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res　63：394-399, 2003

28) Li B, Lin J, Vanroey M, et al：Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol　125：76-87, 2007

29) Murata S, Ladle BH, Kim PS, et al：OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8＋T cell tolerance to an endogenous tumor antigen. J Immunol　176：974-983, 2006

30) Li B, Lalani AS, Harding TC, et al：Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res　12：6808-6816, 2006

31) Quezada SA, Peggs KS, Curran MA, et al：CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest　116：1935-1945, 2006

32) Li B, VanRoey M, Wang C, et al：Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res　15：1623-1634, 2009

33) Driessens G, Hoffmann P, Pouwels M, et al：Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma. J Immunother　32：140-144, 2009

34) Chu Y, Wang LX, Yang G, et al：Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother　29：367-380, 2006

35) Lin JM, Li B, Rimmer E, et al：Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside. Exp Hematol　36：319-328, 2008

36) Wada S, Yoshimura K, Hipkiss EL, et al：Cyclophosphamide augments antitumor immunity：studies in an autochthonous prostate cancer model. Cancer Res　69：4309-4318, 2009

37) Hodi FS, Butler M, Oble DA, et al：Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA　105：3005-3010, 2008

38) Serafini P, Carbley R, Noonan KA, et al：High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res　64：6337-6343, 2004

39) Filipazzi P, Valenti R, Huber V, et al：Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol　25：2546-2553, 2007

40) Massagué J：TGFbeta in Cancer. Cell　134：215-230, 2008

41) Yu H, Pardoll D, Jove R：STATs in cancer inflammation and immunity：a leading role for STAT3. Nat Rev Cancer　9：798-809, 2009

42) Steinman RM, Banchereau J：Taking dendritic cells into medicine. Nature　449：419-426, 2007

43) naba K, Inaba M, Romani N, et al：Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med　176：1693-1702, 1992

targeting. Nat Rev Immunol　7：790-802, 2007